Projects per year
Search results
-
Active
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Ganguly, S. (PI), Heslop, H. (Key Personnel), Mai, H. P. (Key Personnel), Pingali, S. R. (Key Personnel) & Shah, S. (Key Personnel)
1/28/25 → …
Project: Clinical Trial
-
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia
Shah, S. (PI), Ganguly, S. (Key Personnel), Guan, J. (Key Personnel), Mai, H. P. (Key Personnel) & Pingali, S. R. (Key Personnel)
10/25/24 → …
Project: Clinical Trial
-
Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) with Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib
Pingali, S. R. (PI), Ganguly, S. (Key Personnel), Guan, J. (Key Personnel), Mai, H. P. (Key Personnel), Mathur, S. (Key Personnel), Shah, S. (Key Personnel) & Yi, Q. (Key Personnel)
7/29/24 → …
Project: Clinical Trial
-
IMPACT ON SURVIVAL OF FAITH-BASED SPIRITUAL CARE OR PSYCHOTHERAPY COMBINED WITH PALLIATIVE CARE VERSUS PALLIATIVE CARE ALONE IN PATIENTS WITH NON-CURATIVE MALIGNANCIES
Mai, H. P. (PI), Abdelrahim, M. (Key Personnel), Ganguly, S. (Key Personnel), Guan, J. (Key Personnel), Heyne, K. (Key Personnel), Mathur, S. (Key Personnel), Niravath, P. A. (Key Personnel), Pingali, S. R. (Key Personnel), Puri, A. (Key Personnel), Shah, S. (Key Personnel), Singh, M. (Key Personnel), Sun, K. (Key Personnel), Venta, L. A. (Key Personnel) & Zhang, J. (Key Personnel)
6/19/24 → …
Project: Clinical Trial
-
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)
Ganguly, S. (PI), Mai, H. P. (Key Personnel), Pingali, S. R. (Key Personnel) & Shah, S. (Key Personnel)
3/21/24 → …
Project: Clinical Trial
-
Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Niravath, P. A. (PI), Guan, J. (Key Personnel), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Mathur, S. (Key Personnel), Puri, A. (Key Personnel) & Sun, K. (Key Personnel)
7/15/21 → …
Project: Clinical Trial
-
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR
Mai, H. P. (PI)
7/6/21 → 7/5/31
Project: Non Profit
-
ALLIANCE A221602: OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Darcourt, J. (PI), Mai, H. P. (PI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Geyer, C. E. (CoI), Heyne, K. (CoI) & Niravath, P. A. (CoI)
3/6/20 → 3/5/45
Project: Non Profit
-
Not started
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)
Sun, K. (PI), Mai, H. P. (Key Personnel) & Niravath, P. A. (Key Personnel)
Project: Clinical Trial
-
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast
Mai, H. P. (PI), Niravath, P. A. (Key Personnel), Puri, A. (Key Personnel), Sun, K. (Key Personnel) & Templeton, S. (Key Personnel)
Project: Clinical Trial
-
BO41843: Phase III_GDC-9545 RO7197597_Breast Cancer_Roche BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Niravath, P. A. (PI), Chang, J. C. (Key Personnel), Mai, H. P. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
Converting HR Breast Cancer Into an Individualized Vaccine
Chang, J. C. (PI), Mai, H. P. (Key Personnel), Niravath, P. A. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
Ganguly, S. (PI), Mai, H. P. (Key Personnel), Petkova, J. (Key Personnel), Pingali, S. R. (Key Personnel) & Shah, S. (Key Personnel)
Project: Clinical Trial
-
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (INTEGRAL)
Niravath, P. A. (PI), Mai, H. P. (Key Personnel), Sun, K. (Key Personnel) & Venta, L. A. (Key Personnel)
Project: Clinical Trial
-
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Ganguly, S. (PI), Mai, H. P. (Key Personnel), Petkova, J. (Key Personnel), Pingali, S. R. (Key Personnel) & Shah, S. (Key Personnel)
Project: Clinical Trial
-
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Niravath, P. A. (PI), Antosh, D. (Key Personnel), Chang, J. C. (Key Personnel), Guan, J. (Key Personnel), High, R. A. (Key Personnel), Hoopes, S. (Key Personnel), Mai, H. P. (Key Personnel), Singh, M. (Key Personnel), Sun, K. (Key Personnel) & Zaid, T. (Key Personnel)
Project: Clinical Trial
-
Acupuncture Trial
Niravath, P. A. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Singh, M. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Sun, K. (PI), Chang, J. C. (Key Personnel), Mai, H. P. (Key Personnel), Niravath, P. A. (Key Personnel) & Templeton, S. (Key Personnel)
Project: Clinical Trial
-
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Niravath, P. A. (PI), Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Singh, M. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Niravath, P. A. (PI), Arentz, C. (Key Personnel), Guan, J. (Key Personnel), Mai, H. P. (Key Personnel), Puri, A. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial